Twist Bioscience (NASDAQ:TWST) Director Jan Johannessen Sells 12,000 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Jan Johannessen sold 12,000 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $56.12, for a total value of $673,440.00. Following the sale, the director owned 17,754 shares of the company’s stock, valued at approximately $996,354.48. The trade was a 40.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Twist Bioscience Stock Performance

Shares of TWST opened at $52.95 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The stock has a 50-day moving average of $51.83 and a 200-day moving average of $42.45. The company has a market cap of $3.30 billion, a PE ratio of -39.81 and a beta of 2.22. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $66.06.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. During the same quarter in the prior year, the business earned ($0.66) earnings per share. The business’s quarterly revenue was up 19.3% on a year-over-year basis. On average, equities research analysts predict that Twist Bioscience Corporation will post -1.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new position in Twist Bioscience in the third quarter worth $28,000. Smartleaf Asset Management LLC grew its position in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after acquiring an additional 442 shares in the last quarter. Strs Ohio purchased a new position in Twist Bioscience in the first quarter worth $33,000. Strategic Advocates LLC grew its position in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. grew its position in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms have commented on TWST. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research report on Friday, March 27th. Evercore lifted their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Guggenheim lifted their price target on shares of Twist Bioscience from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Leerink Partners raised shares of Twist Bioscience from a “market perform” rating to an “outperform” rating and set a $70.00 price target on the stock in a report on Tuesday, May 5th. Finally, Robert W. Baird lifted their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $56.57.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.